Added to YB: 2026-04-24
Pitch date: 2026-04-23
HAE [bullish]
Haemonetics Corporation
Author Info
Colubeat Investment Desk writes and shares analysis on exceptional companies with sustainable moats. Sometimes undervalued, always high quality. Sign up for the newsletter.
Company Info
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally.
Market Cap
$2.8B
Pitch Price
N/A
Price Target
148.00 (+142%)
Dividend
N/A
EV/EBITDA
10.15
P/E
16.75
EV/Sales
2.81
Sector
Health Care Equipment and Supplies
Category
value
HAEMONETICS (NYSE: $HAE)
HAE: Medtech w/ 3 #1 positions (plasma collection, TEG, vascular closure). Reported rev -2.7%, but organic +7.5% ex-CSL ($100M annual headwind ending FY27). Plasma grows 20.2% organically, 36% margins via razorblade model; NexLynk software lock-in defends 50% share. Hospital integrating OpSens (smart) & Attune (PFA pivot impaired $188M thesis). Vivasure FDA approval = $35-60M FY28 upside (TAVR large-bore). FCF $260M TTM (110% conversion), 7.8% yield. Net debt 2.4x. Trades 12x FY26 EPS vs peers 15-18x. Base: $103 PT (20% IRR). Bear $49 (recession). Bull $148 (share gains). Risks: reimbursement cuts, patent loss, customer concentration, Vivasure delay.
Read full article (19 min)